Please login to the form below

Not currently logged in
Email:
Password:

isavuconazole

This page shows the latest isavuconazole news and features for those working in and with pharma, biotech and healthcare.

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea bags $72m upfront from Pfizer for antifungal license

Cresemba (isavuconazole) was approved in 2015 in both intravenous and oral formulations to treat adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen in immunocompromised patients

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    isavuconazole. Cresemba. Invasive aspergillosis/mucomycosis. triazole antifungal. Basilea/Astellas. USA. ixazomib. Ninlaro. multiple myeloma.

  • Shire and Baxalta drugs among CHMP's latest recommendations Shire and Baxalta drugs among CHMP's latest recommendations

    Basilea's orphan drug Cresemba (isavuconazole), for the treatment of aspergillosis and mucormycosis - two life-threatening diseases with limited treatment options. •

  • FDA panel backs new antifungal Cresemba FDA panel backs new antifungal Cresemba

    The panel gave its blessing to Cresemba ( isavuconazole) in both intravenous and oral formulations as treatments for adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen ... Isavuconazole has

  • Orphan status in US for Astellas/ Basilea antifungal Orphan status in US for Astellas/ Basilea antifungal

    Orphan status in US for Astellas/ Basilea antifungal. Isavuconazole is being developed as a treatment for invasive aspergillosis. ... Astellas and Basilea are also developing isavuconazole for candidaemia/invasive candidiasis, the most common form of

  • Pharma deals for June 2012 Pharma deals for June 2012

    This deal allows Basilea to support the regulatory filing on the antibiotic ceftobiprole for the treatment of pneumonia and to complete its phase III study for the antifungal isavuconazole (partnered with

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    We have also signed a deal with Basilea for Isavuconazole. In oncology, we've entered an agreement with AVEO Pharmaceuticals to commercialise and develop tivozanib, which has significant potential in a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics